Alexion’s Ultomiris Wins English Funding, Janssen’s Erleada Rejected
NICE Guidance Due On Astellas’s Xtandi For Prostate Cancer
Executive Summary
Recommendations this week from health technology assessment body NICE relate to the treatment of two rare blood disorders with Ultomiris, and treating prostate cancer with Erleada.